Department of Psychiatry, Saitama Medical Center, Saitama Medical School, Japan.
Breast Cancer. 2012 Apr;19(2):147-52. doi: 10.1007/s12282-010-0220-y. Epub 2010 Sep 3.
Most previous studies about anxiety and depression in patients undergoing radiotherapy have only measured the quantity of general depression and anxiety and have not studied specific periods of involvement. The aim of this study was to assess anxiety and depression among early breast cancer patients, and the anxiety experienced immediately before and after radiotherapy.
Women who started radiotherapy for stage I or II breast cancer (n = 172) were asked to answer two questionnaires: the Hospital Anxiety and Depression Scale (HADS) and Radiotherapy Categorical Anxiety Scale immediately before and after radiation therapy.
The results showed that the mean scores of anxiety and depression (HADS and Radiotherapy Categorical Anxiety Scale) decreased after radiotherapy. The mean score of depression (HAD-D) in the group receiving conventional radiotherapy was higher than in those receiving hypofractionated radiotherapy before and after radiotherapy. The mean scores of anxiety and depression (HADS) in the endocrine therapy group were lower than in the group without endocrine therapy before treatment. However, the scores after treatment of both groups were not significant.
Some intervention may be needed to decrease the temporary anxiety and depression raised during radiotherapy for early stage breast cancer patients. This is especially so for patients who do not receive concurrent endocrine therapy and choose the conventional radiotherapy course.
大多数关于接受放疗的患者的焦虑和抑郁的既往研究仅测量了一般抑郁和焦虑的数量，而没有研究特定的发病期。本研究旨在评估早期乳腺癌患者的焦虑和抑郁，以及放疗前后即刻的焦虑程度。
172 名接受 I 期或 II 期乳腺癌放疗的女性被要求回答两份问卷：医院焦虑和抑郁量表（HADS）和放疗分类焦虑量表，分别在放疗前和放疗后立即作答。
结果显示，放疗后焦虑和抑郁的平均评分（HADS 和放疗分类焦虑量表）降低。接受常规放疗组的抑郁（HAD-D）平均分在放疗前后均高于接受亚分割放疗组。接受内分泌治疗组的焦虑和抑郁平均评分（HADS）在治疗前均低于未接受内分泌治疗组。然而，两组治疗后的评分均无显著差异。
对于接受早期乳腺癌放疗的患者，可能需要一些干预措施来减轻放疗期间暂时出现的焦虑和抑郁。对于不接受同期内分泌治疗且选择常规放疗方案的患者尤其如此。
